PTD-DBM vs Hexapeptide-9
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Also: Collaxyl, Collaxyl IS
Hexapeptide-9 is a collagen-inspired signaling peptide sold as Collaxyl (originally from Vincience, now Ashland) for anti-wrinkle and firming skincare. The idea is that a small repeat of a collagen sequence nudges skin cells to rebuild the junction between the outer and inner skin. It is a cosmetic ingredient, and the evidence for the original peptide is mostly old, small and company-run, although a 2025 trial on a modified cyclic version is more interesting.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to Hexapeptide-9 (Limited Research).
Detailed Comparison
| Attribute | PTD-DBM | Hexapeptide-9 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. | Hexapeptide-9 is Gly-Pro-Gln-Gly-Pro-Gln, a repeat taken from collagen sequences. Ashland says the sequence is found in collagen IV and XVII and works as a matrikine, a matrix fragment that signals cells to make more matrix proteins. The claimed targets are the dermal-epidermal junction (collagen IV, laminin-5, integrins) and collagen production. The original patent describes it as designed to improve cell adhesion and possibly support matrix production. One weakness is stability: the linear peptide is easily broken down by collagen-digesting enzymes, which is why a Chinese group built a ring-shaped (cyclized) version to make it last longer in skin. |
| Common Dosing | Supplied as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water approximates the ~6 mg/mL used in the mouse study Once daily to the scalp in most community-reported routines | Low single-digit percent of the ingredient in a finished product Once or twice daily |
| Administration | Topical (applied to skin) in published research; usually co-applied with valproic acid | Topical (serums, creams) |
| Typical Duration | Applied over several weeks in animal studies | 4-8 weeks in studies; ongoing use to maintain any effect |
| Best Time to Take | Not established (topical in animal studies) | Morning and/or evening, on clean skin |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a topical liquid of about 6 mg/mL PTD-DBM plus about 72 mg/mL valproic acid outperformed roughly 2% minoxidil in that model (the study reported these as solution concentrations: 2 mM, 500 mM, and 100 mM). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. | The oldest human data is a 2004 study from Vincience, the lab behind Collaxyl: a double-blind, placebo-controlled test of a gel containing 3% of a 'collagen-like hexapeptide' plus a 1% booster ingredient, applied around the eyes of 20 women for four weeks. It reported fewer and shallower wrinkles on skin replicas, but the booster and the small size mean it cannot prove the peptide alone did the work. Supplier material cites other 28-day studies in about 20 volunteers that we could not trace to journals. The newest and best-designed study is a 2025 randomized, double-blind trial in the Journal of Cosmetic Dermatology (96 adults aged 30-55 in China) comparing a cyclized hexapeptide-9 serum at 0.002% with 0.002% retinol and a vehicle for 56 days. The cyclized peptide beat both on wrinkle, elasticity and hydration measures, with no treatment-related side effects. Two caveats: it tested a modified molecule, not the Collaxyl peptide in most products, and several authors are affiliated with cosmetic companies. Bottom line: the concept has some support, the cyclic version looks promising, but regular hexapeptide-9 in a store-bought cream rests on thin evidence. |
Frequently Asked Questions: PTD-DBM vs Hexapeptide-9
What is the difference between PTD-DBM and Hexapeptide-9?
PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. Hexapeptide-9 is a skin & hair peptide that hexapeptide-9 is a collagen-inspired signaling peptide sold as collaxyl (originally from vincience, now ashland) for anti-wrinkle and firming skincare. the idea is that a small repeat of a collagen sequence nudges skin cells to rebuild the junction between the outer and inner skin. it is a cosmetic ingredient, and the evidence for the original peptide is mostly old, small and company-run, although a 2025 trial on a modified cyclic version is more interesting. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PTD-DBM or Hexapeptide-9?
Neither is universally "better" - the choice depends on your specific goals. PTD-DBM is typically used for skin & hair purposes, while Hexapeptide-9 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PTD-DBM and Hexapeptide-9 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PTD-DBM and Hexapeptide-9 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.